Schwab Charles Investment Management Inc. raised its position in DENTSPLY SIRONA Inc (NASDAQ:XRAY) by 4.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 830,722 shares of the medical instruments supplier’s stock after buying an additional 35,359 shares during the period. Schwab Charles Investment Management Inc. owned 0.37% of DENTSPLY SIRONA worth $41,794,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. NuWave Investment Management LLC bought a new stake in DENTSPLY SIRONA in the fourth quarter valued at approximately $121,000. Focused Wealth Management Inc increased its stake in DENTSPLY SIRONA by 79.2% in the fourth quarter. Focused Wealth Management Inc now owns 2,600 shares of the medical instruments supplier’s stock valued at $171,000 after purchasing an additional 1,149 shares in the last quarter. Capital One National Association bought a new stake in DENTSPLY SIRONA in the fourth quarter valued at approximately $204,000. Boston Common Asset Management LLC bought a new stake in DENTSPLY SIRONA in the fourth quarter valued at approximately $212,000. Finally, Dupont Capital Management Corp increased its stake in DENTSPLY SIRONA by 85.0% in the fourth quarter. Dupont Capital Management Corp now owns 3,308 shares of the medical instruments supplier’s stock valued at $218,000 after purchasing an additional 1,520 shares in the last quarter. Hedge funds and other institutional investors own 93.85% of the company’s stock.
DENTSPLY SIRONA traded up $0.38, reaching $44.89, during mid-day trading on Thursday, MarketBeat Ratings reports. 3,905,700 shares of the company’s stock were exchanged, compared to its average volume of 2,503,673. DENTSPLY SIRONA Inc has a one year low of $41.64 and a one year high of $68.98. The firm has a market cap of $9.87 billion, a price-to-earnings ratio of 16.88, a P/E/G ratio of 2.24 and a beta of 1.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.46 and a current ratio of 2.23.
DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Sunday, May 6th. The medical instruments supplier reported $0.45 EPS for the quarter, beating the consensus estimate of $0.42 by $0.03. DENTSPLY SIRONA had a negative net margin of 38.32% and a positive return on equity of 8.63%. The firm had revenue of $956.10 million for the quarter, compared to analyst estimates of $942.20 million. During the same period last year, the firm earned $0.49 EPS. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. sell-side analysts anticipate that DENTSPLY SIRONA Inc will post 2.58 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, July 13th. Shareholders of record on Friday, June 29th will be issued a $0.0875 dividend. This represents a $0.35 annualized dividend and a yield of 0.78%. The ex-dividend date of this dividend is Thursday, June 28th. DENTSPLY SIRONA’s dividend payout ratio is currently 13.16%.
In other news, Director Michael C. Alfano sold 1,404 shares of the firm’s stock in a transaction that occurred on Wednesday, May 30th. The shares were sold at an average price of $45.83, for a total value of $64,345.32. Following the sale, the director now directly owns 13,458 shares in the company, valued at approximately $616,780.14. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michael J. Coleman sold 6,038 shares of the firm’s stock in a transaction that occurred on Friday, June 1st. The shares were sold at an average price of $43.97, for a total transaction of $265,490.86. Following the completion of the sale, the director now owns 26,960 shares in the company, valued at $1,185,431.20. The disclosure for this sale can be found here. Over the last three months, insiders sold 7,856 shares of company stock worth $349,153. Insiders own 1.93% of the company’s stock.
XRAY has been the subject of several recent analyst reports. Barrington Research reaffirmed a “buy” rating and issued a $69.00 target price on shares of DENTSPLY SIRONA in a research note on Tuesday, March 27th. JPMorgan Chase & Co. lowered their price objective on shares of DENTSPLY SIRONA from $75.00 to $70.00 and set an “overweight” rating for the company in a research report on Monday, March 5th. BidaskClub downgraded shares of DENTSPLY SIRONA from a “sell” rating to a “strong sell” rating in a research report on Wednesday, February 28th. Credit Suisse Group lowered their price objective on shares of DENTSPLY SIRONA from $73.00 to $69.00 and set an “outperform” rating for the company in a research report on Friday, March 2nd. Finally, Cleveland Research reissued a “hold” rating on shares of DENTSPLY SIRONA in a research report on Thursday, April 5th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company’s stock. DENTSPLY SIRONA presently has an average rating of “Hold” and a consensus price target of $62.23.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.